Net Good IndexSubmit a correction

Insilico Medicine

Pharma.AI

A family is a named generation or product line. Scores below are the sum of its named releases and any documented internal systems in the same line.

Benefit

+0.17

Harm

0.00

Net Good

0.17

Releases

Leaderboard

RankModelOrganizationBenefitHarmNetEventsLast impact
57Pharma.AI Internal Research Model

Pharma.AI · internal / unreleased

Insilico Medicine+0.170.000.1713 Jun 2025

Timeline

  • Benefit
  • Harm
  • Net
00.200.400.600.801Jul 25Oct 25Jan 26Apr 26Jul 26Oct 26

Events

Benefit3 Jun 2025

Rentosertib, an AI-designed TNIK inhibitor, posts Phase 2a IPF results

Insilico Medicine’s rentosertib (ISM001-055), discovered with generative models, met a Phase 2a safety endpoint in 71 IPF patients; the 60 mg daily arm showed a mean FVC gain of 98.4 ml versus a 20.3 ml decline on placebo.

Medicine & HealthverifiedTier 2 Notable+0.17